Zepp Health Corp

Zepp Health Corp(ZEPP)股票分析

$2.770

-0.142 (-5.14%)收盘时

Loading chart…
最高
2.940
开盘
2.860
成交量加权均价
2.65
成交量
161.24K
市值
35.99M
最低
2.230
成交额
426.74K
企业价值/息税折旧摊销前利润(TTM)
-2.39

Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has one reportable segment: Amazfit-branded products.

AI 分析 of Zepp Health Corp (ZEPP)

卖出

Zepp Health Corp is not a good buy right now due to a current price of $3.02 and a concerning RSI of 5.838, indicating extreme oversold conditions. The company has reported a staggering year-to-date change of -89.23% and a one-year change of -93.94%, reflecting severe financial distress. Additionally, the forward P/E ratio stands at 3.124, which may seem low but is overshadowed by the company's ongoing net losses, including a net loss of $11.33 million in Q2 2026. The main risk is the widening operating loss and declining revenue expectations for Q3 2026, which could further impact stock performance.

估值指标

Zepp Health Corp(ZEPP)当前预期市盈率为 3.12,5 年平均预期市盈率为 -38.31。

预期市盈率

合理
5 年均值 P/E
-38.31
当前P/E
3.12
高估
83.60
低估
-160.21

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-11.69
当前EV/EBITDA
-2.39
高估
22.14
低估
-45.52

预期市销率

合理
5 年均值 P/S
0.37
当前P/S
0.02
高估
0.96
低估
-0.22

持有 ZEPP 的大户

T

Trivest Advisors Ltd

+ 持有ZEPP

-14.92%

3个月收益率

事件时间线

2026-09-22 (ET)

07:30:00

Amazfit Launches T-Rex Dual Solar Smartwatch at $649.99

2026-06-08 (ET)

21:40:00

Q1 Revenue Reaches $51.5 Million

2026-05-13 (ET)

07:30:00

Amazfit Launches Cheetah 2 Ultra at $599.99

2026-04-16 (ET)

07:10:00

Amazfit Launches Cheetah 2 Pro Sports Watch at $449.99

2026-04-15 (ET)

07:10:00

Zepp Health Signs Three-Year Global Partnership with HYROX

资讯

ZEPP 常见问题 —— 由 Alphio AI 解答

Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has one reportable segment: Amazfit-branded products. It operates in the Technology sector (ELECTRONIC COMPUTERS industry).

Zepp Health Corp is not a good buy right now due to a current price of $3.02 and a concerning RSI of 5.838, indicating extreme oversold conditions. The company has reported a staggering year-to-date change of -89.23% and a one-year change of -93.94%, reflecting severe financial distress. Additionally, the forward P/E ratio stands at 3.124, which may seem low but is overshadowed by the company's ongoing net losses, including a net loss of $11.33 million in Q2 2026. The main risk is the widening operating loss and declining revenue expectations for Q3 2026, which could further impact stock performance.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易